Benefits of Abemaciclib in HR+/HER2- Node-Positive EBC

Dear Dr. Renukaprasad A R, Do you know how effective abemaciclib is for patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor-2 negative (HER2-) early breast cancer (EBC)? Eli Lilly and Docplexus are hosting a Ramiven® EBC launch program and a panel discussion to address the clinical benefits of abemaciclib in both HR+/HER2- Node-Positive EBC and metastatic breast cancer with Dr. Shaheenah Dawood (UAE), Dr. Vamshi Krishna, Dr. Amit Rauthan, Dr. Vijay Agarwal, Dr. Bharat A. Vaswani, and Dr. Satheesh C. T. Join us TODAY at 07:30 PM IST. Looking forward to your active participation in this launch event. Session Highlights - Opening Remarks: Dr. Satheesh CT Disease burden and unmet needs in HR+ HER2- EBC: Dr. Amit Rauthan Current trials in the EBC setting & monarchE study: Dr. Shaheenah Dawood Significance of abemaciclib in the MBC setting: Dr. Vijay Agarwal Panel Discussion (moderated by Dr. Vamshi Krishna) Click to Join Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*